Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024
2024年4月16日 - 1:00AM
ビジネスワイヤ(英語)
- Results of ACTISAVE phase 2/3 clinical study in stroke
expected in Q2 2024
- Presentation of results during ESOC from 15 to 17 May
2024
Regulatory News:
ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage
biopharmaceutical company developing glenzocimab, an innovative
drug for the treatment of cardiovascular emergencies, focusing
stroke, announces today its participation in the European Stroke
Organization Conference (ESOC) 2024, to be held from 15 to 17 May
2024 in Basel, Switzerland.
ESOC is the leading European forum for stroke research and the
preferred platform for the publication of major clinical trial
data.
At this conference, the Company will present the results of its
phase 2/3 ACTISAVE study, which is evaluating glenzocimab in the
treatment of stroke: “ACTISAVE Clinical Trial: Efficacy and Satefy
of Glenzocimab on Top of Thrombolysis with or without Mechanical
Thrombectomy” - Abstract N°357 - Presentation by Pr. Martin
K�hrmann.
As a reminder, ACTISAVE (NCT05070260) is an international,
adaptive, multicenter, randomized, double-blind,
placebo-controlled, parallel-group Phase 2/3 study evaluating the
safety and efficacy of a single dose of glenzocimab used in
combination with the standard of care (thrombolysis +/-
thrombectomy) for acute ischemic stroke. Deployed in the United
States, Europe, Israel, and United Kingdom, ACTISAVE has enrolled
438 patients, of whom about 40% have undergone mechanical
thrombectomy.
Sophie BINAY, Chief Operating Officer and Chief Scientific
Officer, stated: "We are looking forward to the results of our
phase 2/3 clinical trial ACTISAVE in stroke, which we expect to be
available in the next few weeks and which will represent a major
milestone for Acticor Biotech, its collaborators, investigators,
stakeholders and above all for stroke patients. These results will
be presented at ESOC 2024, Europe's leading stroke research
conference. We are convinced that glenzocimab is a promising drug
candidate for tackling the major global medical challenge
represented by stroke.”
About ACTICOR BIOTECH
Acticor Biotech is a clinical-stage biopharmaceutical company
developing glenzocimab, an innovative drug for the treatment of
cardiovascular emergencies, particularly ischemic stroke.
Positive results from the phase 1b/2a study, ACTIMIS, published
in January 2024 in the Lancet Neurology (link to publication)
confirmed the safety profile of glenzocimab and showed a reduction
in mortality and intracerebral haemorrhage in the
glenzocimab-treated group of stroke patients. These results were
confirmed by a post-hoc analysis of brain imaging at 0 and 24 hours
using artificial intelligence (Brainomix, UK). This independent
analysis confirmed the reduction in the number and volume of
intracerebral lesions in patients treated with glenzocimab.
The efficacy of glenzocimab is currently being evaluated in a
phase 2/3 international trial, ACTISAVE, with clinical results
expected in the 2nd quarter of 2024.
In July 2022, Acticor Biotech obtained "PRIME" status from the
European Medicines Agency (EMA) for glenzocimab in the treatment of
stroke. This designation enables the company to strengthen its
interactions and obtain early dialogues with regulatory
authorities.
Acticor Biotech is backed by a panel of European and
international investors (Mediolanum farmaceutici, Karista, Go
Capital, Newton Biocapital, CMS Medical Venture Investment (HK)
Limited, A&B (HK) Limited, Anaxago, and the Armesa Foundation)
and has been listed on Euronext Growth Paris since November 2021
(ISIN: FR0014005OJ5 - ALACT).
For further information, please visit :
https://www.acticor-biotech.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240415887570/en/
ACTICOR BIOTECH Gilles AVENARD, MD General Manager and
founder gilles.avenard@acticor-biotech.com T. : +33 (0)6 76 23 38
13
Sophie BINAY, PhD Chief Operating Officer and Scientific
Director Sophie.binay@acticor-biotech.com T. : +33 (0)6 76 23 38
13
NewCap Mathilde BOHIN Investor Relations
acticor@newcap.eu T. : +33 (0)1 44 71 94 95
NewCap Arthur ROUILLÉ Media Relations acticor@newcap.eu
T. : +33 (0)1 44 71 00 15
Acticor Biotech (EU:ALACT)
過去 株価チャート
から 4 2024 まで 5 2024
Acticor Biotech (EU:ALACT)
過去 株価チャート
から 5 2023 まで 5 2024